JP Morgan Chase
TARS icon

JP Morgan Chase’s Tarsus Pharmaceuticals TARS Stock Holding History

JP Morgan Chase’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.68M Buy
139,981
+109,503
+359% +$7M ﹤0.01% 2934
2026
Q1 		$2.04M Sell
30,478
-26,168
-46% -$1.83M ﹤0.01% 4082
2025
Q4 		$4.64M Sell
56,646
-20,544
-27% -$1.53M ﹤0.01% 3379
2025
Q3 		$4.59M Sell
77,190
-63,420
-45% -$3.12M ﹤0.01% 3446
2025
Q2 		$5.7M Buy
140,610
+112,637
+403% +$5.07M ﹤0.01% 3027
2025
Q1 		$1.44M Sell
27,973
-101,211
-78% -$5M ﹤0.01% 4102
2024
Q4 		$7.15M Sell
129,184
-310,983
-71% -$14.1M ﹤0.01% 3024
2024
Q3 		$14.5M Buy
440,167
+420,057
+2,089% +$11.8M ﹤0.01% 2289
2024
Q2 		$547K Sell
20,110
-33,229
-62% -$1.12M ﹤0.01% 4643
2024
Q1 		$1.94M Buy
53,339
+27,769
+109% +$816K ﹤0.01% 3867
2023
Q4 		$518K Buy
25,570
+3,468
+16% +$57.9K ﹤0.01% 4772
2023
Q3 		$393K Buy
22,102
+2,903
+15% +$51.4K ﹤0.01% 4627
2023
Q2 		$347K Buy
19,199
+4,230
+28% +$67.3K ﹤0.01% 4722
2023
Q1 		$188K Buy
14,969
+3,618
+32% +$52.9K ﹤0.01% 5102
2022
Q4 		$167K Buy
11,351
+1,309
+13% +$21.7K ﹤0.01% 5120
2022
Q3 		$172K Buy
10,042
+349
+4% +$5.54K ﹤0.01% 5025
2022
Q2 		$142K Buy
9,693
+5,739
+145% +$86.2K ﹤0.01% 5241
2022
Q1 		$67K Sell
3,954
-170,782
-98% -$3.17M ﹤0.01% 5681
2021
Q4 		$3.93M Buy
174,736
+171,499
+5,298% +$4.46M ﹤0.01% 3265
2021
Q3 		$70K Sell
3,237
-1,925
-37% -$47.6K ﹤0.01% 5728
2021
Q2 		$150K Sell
5,162
-5,750
-53% -$180K ﹤0.01% 5378
2021
Q1 		$352K Sell
10,912
-5,871
-35% -$217K ﹤0.01% 4881
2020
Q4 		$694K Buy
+16,783
New +$478K ﹤0.01% 4183

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase's TARS Position: Q2 2026 in Review

JP Morgan Chase increased its Tarsus Pharmaceuticals (TARS) stake by 359% in Q2 2026, buying an estimated $7M and bringing the position to 139,981 shares worth $8.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

JP Morgan Chase first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $14.5M in Q3 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • JP Morgan Chase held 139,981 shares of Tarsus Pharmaceuticals worth $8.68M as of Q2 2026.
  • JP Morgan Chase bought 109,503 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $7M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2934 holding.
  • JP Morgan Chase first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Tarsus Pharmaceuticals position peaked at $14.5M in Q3 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.